Opinions
Brian Acker, CA
Edwards Lifesciences Corp
EW-N
DON'T BUY
Aug 30, 2018
$143.800
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
PAST TOP PICK
(A Top Pick Mar 19/18, Up 22%) He owns this through the IHI ETF. Their catheter device accounts for 60% of revenue and results in less-invasive surgeries which results in higher patient turnover in hospitals (which are expensive). This is better for patients and hospitals. They continue to take market share.
biotechnology
pharmaceutical
COMMENT
He has owned IRTC-O in the past. It is in the medical device space and has equipment that looks for heart arrhythmia and loads the data to the cloud. The market has not yet said this stock has taken a positive turn yet. Earnings are growing and it is growing into its share price. He wants to see it break above $85-$87 before getting back in. He would prefer holding EW-N
biotechnology
pharmaceutical
Advertising
When it came down to his model price it was the only buying opportunity there was in the last eight years. He loves the company. Model price is $99.94, a 30% premium that it is trading at. He can only wish for a pull back.